EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Active Surveillance in Prostate Cancer: Is it a Myth or Reality in the Current Age of Treatment Options?

Pushan Prabhakar, Mohamed Javid Raja Iyub, Deerush Kannan Sakthivel, Murugesan Manoharan

UroCancer Clinics of India · 2025-01 · 3 (1) · 3-7

DOI: 10.4103/ucci.ucci_19_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift UroCancer Clinics of India, online erschienen am 18.11.2026. Verfasst von Pushan Prabhakar und 3 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Active surveillance (AS) is a safe management strategy for appropriately selected cases with low-risk and, in some instances, favorable intermediate risk prostate cancer, too. This chapter highlights the development of AS, the rationale for use, the current protocols, and how they can be integrated into practice. The main goal of AS is to reduce overtreatment and any definitive treatment (radical prostatectomy or radiation therapy) associated morbidity by structured monitoring of the disease progression through serial prostate-specific antigen (PSA) testing, a digital rectal examination, magnetic resonance imaging (MRI), and repeat surveillance biopsies. Patient selection is critical to AS, with the common consensus between multiple guidelines being Gleason grade group (GG) 1 disease, PSA 0.15, ≤cT2a, and low tumor volume. In select cases, GG2 with favorable disease characteristics may be offered AS. Modern AS follow-up protocols are structured with PSA monitoring (every 6 months), digital rectal examination (every 12 months), a systematic repeat biopsy (every 1–3 years), and a prostate MRI (every 12 months). Long-term outcomes across large cohorts demonstrate effective oncological results, with 10-year cancer-specific survival exceeding 98% and metastasis-free survival over 99%. In addition, these cohorts exhibit high rates of treatment-free survival. This chapter highlights AS as a patient-centered approach that is safe, effective, and a current treatment option implemented in modern prostate cancer management.

Zitieren

APA

Prabhakar, P., Iyub, M. J. R., Sakthivel, D. K., & Manoharan, M. (2025). Active Surveillance in Prostate Cancer: Is it a Myth or Reality in the Current Age of Treatment Options?. UroCancer Clinics of India, 3(1), 3-7. https://doi.org/10.4103/ucci.ucci_19_25

Vancouver

Prabhakar P, Iyub MJR, Sakthivel DK, Manoharan M. Active Surveillance in Prostate Cancer: Is it a Myth or Reality in the Current Age of Treatment Options?. UroCancer Clinics of India. 2025;3(1):3-7. doi:10.4103/ucci.ucci_19_25

BibTeX
@article{Prabhakar2025,
  author = {Prabhakar, Pushan and Iyub, Mohamed Javid Raja and Sakthivel, Deerush Kannan and Manoharan, Murugesan},
  title = {Active Surveillance in Prostate Cancer: Is it a Myth or Reality in the Current Age of Treatment Options?},
  journal = {UroCancer Clinics of India},
  year = {2025},
  volume = {3},
  number = {1},
  pages = {3--7},
  doi = {10.4103/ucci.ucci_19_25}
}
Kostenlos starten →